# SHORT COMMUNICATION From RAGs to riches: Using large language models to write documents for clinical trials

Nigel Markey<sup>1</sup>, Ilyass El-Mansouri<sup>2</sup>, Gaetan Rensonnet<sup>2</sup>, Casper van Langen<sup>1</sup>, Christoph Meier<sup>1</sup>\*

<sup>1</sup> Boston Consulting Group, 80 Charlotte Street, London W1T 4DF, United Kingdom

<sup>2</sup> Boston Consulting Group, 75 Avenue de la Grande Armée, 75016 Paris, France

\* Corresponding author. E-mail: meier.chris@bcg.com

## ABSTRACT

Clinical trials require numerous documents to be written -- protocols, consent forms, clinical study reports and others. Large language models (LLMs) offer the potential to rapidly generate first versions of these documents, however there are concerns about the quality of their output.

Here we report an evaluation of LLMs in generating parts of one such document, clinical trial protocols. We find that an offthe-shelf LLM delivers reasonable results, especially when assessing content relevance and the correct use of terminology. However, deficiencies remain: specifically clinical thinking and logic, and appropriate use of references. To improve performance, we used retrieval-augmented generation (RAG) to prompt an LLM with accurate up-to-date information. As a result of using RAG, the writing quality of the LLM improves substantially, which has implications for the practical useability of LLMs in clinical trial-related writing.

#### **BACKGROUND AND AIMS**

During clinical trials, large volumes of documents need to be written, including protocols, amendments, patient informed consent forms, clinical study reports and others. These documents are critically important for the planning and execution of trials, and are often required by regulation, therefore high-quality writing is essential. Specifically, clinical trial documents must be scientifically and clinically precise and accurate, with correct use of terminology, and must contain appropriate references to literature, regulatory guidelines, and other documents. Due to these stringent requirements, sponsors of clinical trials spend considerable time and resources on trial-related writing. For example, most large pharmaceutical companies each employ tens to hundreds of medical writers and reviewers [1]. Even with these resources, it often takes organizations a long time to write and finalize clinical trial documents. As an illustration, a Clinical Trial Protocol (a description of the design, objectives and an 'operating manual' for the trial) typically has 50-150 or more pages and can take 3-6 months or longer to prepare [2]. A substantial proportion of this time is due to the writing process and, as a result, writing is one of the major rate-limiting steps in the development process.

With pharmaceutical companies under pressure to accelerate trials [3], to recruit patients and submit regulatory documents faster, there is strong interest across the industry in using new approaches to speed up trial-related writing.

In the past few years, large language models (LLMs), a new class of generative artificial intelligence algorithms, have advanced to a point where they can produce near-human-quality writing [4]. Since the arrival of ChatGPT [5], the first widely used tool built on LLMs, there has been interest in using LLMs to write first versions of clinical documents. However, some clinicians and scientists have voiced concerns whether LLMs are robust enough to be used in a clinical context [6].


#### METHODS

Here we report an assessment of an LLM in generating documents for clinical trials, focusing specifically on GPT-4, one of the leading LLMs available today [7], and utilizing it to generate key sections of study protocols. Specifically, we assessed the LLM output in terms of: (i) clinical thinking and logic; (ii) transparency and references; (iii) medical and clinical terminology; and (iv) content relevance and suitability. The assessment methodology is a combination of algorithmic assessment and human expert-based scoring; in both cases, objective criteria are used. An overview of the methodology is given in Figure 1, and further details can be found in the supplementary information.

In total we tested 140 generated document sections, which cover protocols for 14 diseases across different phases of clinical trials. The scores are presented as percentages which indicate the mean score achieved by the generated documents across all diseases and phases and 5 random repetitions.

Our assessment focused on two key sections of a Clinical Trial Protocol document: the endpoints section and the eligibility criteria section. Off-the-shelf GPT-4 and RAGaugmented GPT-4 were prompted with a natural-language user query of the form "Write the {section} section of a Phase {phase} clinical trial protocol in {disease}. Focus on FDA guidance" where section, phase and disease were customizable. For each disease and trial phase, and for each model, 5 endpoints sections and 5 eligibility criteria sections were generated, with potential differences between versions due to the stochastic nature of the underlying LLM models.

As an alternative to off-the-shelf LLM, we set up a retrieval-augmented generation (RAG) LLM framework,



#### Figure 1: Overview of methodology and approach used in this analysis.

(a) Use of off-the-shelf LLMs

- (b) Retrieval-augmented generation (RAG) methodology for enhancing LLMs
- (c) ClinEval methodology for assessing the output of large language models (LLMs)

Further details are described in the Methods section.

combined with a constrained agent approach as follows: based on the user input query above, an LLM-powered decision agent automatically decided which tools to use to fetch relevant context and feed it to an LLM for final summarization and document generation. Tools that were utilized as part of the RAG-augmentation are: An FDA guidance database (vector store databases to access and analyse FDA guidance documents); ClinicalTrials.gov AACT database; SemanticsScholar connector to scrape scientific literature.

The evaluation process was strictly identical for the two models and involved a combination of algorithmic and human expert-based scoring. Details of the scoring methodology and criteria are described in the supplementary information.

## RESULTS

An overview of the result of our assessment is shown in Figure 2. Overall, we find that the off-the shelf LLM delivers reasonable results, specifically good content relevance and suitability (assessment score >80%), and excellent medical and clinical terminology (>99%), meaning that the results

from the first pass of the LLM are deemed correct and appropriate for the vast majority of the protocol sections written. However, for clinical thinking and logic the off-theshelf LLM scores relatively poorly (assessment score just over 40%), meaning that recommendations from the off-theshelf LLM often do not follow the latest guidelines and contain other errors. And since current GPT-4 cannot natively source references, achieving transparency and references is not possible (therefore no assessment score for this dimension).

Here we provide an illustrative example: When we asked the algorithm to draft a Phase 3 protocol for tuberculosis (TB), the off-the-shelf LLM suggested in the eligibility section to exclude patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), diabetes, liver disease and kidney disease. This contrasts with FDA guidelines which state that "Sponsors should include in trials [...], subjects with renal insufficiency, diabetes mellitus, and subjects with hepatic impairment, if feasible. Because of the high incidence of TB in patients coinfected with HIV, subjects with HIV should be included in trials." [8] Given the critical importance of following guidelines, our findings present a challenge to the use of

Clinical trial document dimension	Off-the-shelf LLM (GPT-4)	RAG-augmented LLM (RAG GPT-4)
<ul> <li>Clinical thinking and logic</li> <li>Does the LLM-written text reflect guidelines?</li> <li>Do endpoints and eligibility criteria match guidelines?</li> </ul>	41.4%	79.7%
<b>Orransparency and references</b> Does the LLM-written text include references? Do these exist? Are they factually correct, appropriate?	n/a	78.6%
Medical and clinical terminology     Are endpoints and eligibility criteria defined and     described? Do these have scales and units?	>99%	>99%
• Content relevance and suitability Are endpoints & eligibility criteria aligned with study objectives? Appropriate for phase, disease specific?	82.0%	79.1%

Figure 2: Comparison of off-the-shelf LLM and RAG-augmented LLM

Further information is described in the Methods section and supplementary information

LLMs in the context of clinical trials and may limit the adoption of LLMs in trial-related document writing.

To address the challenge associated with off-the-shelf LLMs, we explored alternative approaches of using LLMs, specifically retrieval-augmented generation (RAG) [9] which has emerged as a promising methodology for incorporating knowledge from external databases [10]. RAG involves providing the LLM with external sources of knowledge, to supplement the model's internal representation of information [9]. As a result of the RAG methodology, the LLM is not primarily used for its memorised knowledge; but instead for its ability to read, synthesize and evaluate information provided to it. An illustration of the RAG methodology is given in Figure 1b.

The output of the RAG-augmented LLM (Figure 2) shows high content relevance and suitability and medical and clinical terminology, comparable to the off-the-shelf LLM. However. the RAG-augmented LLM substantially outperforms the off-the-shelf LLM in terms of clinical thinking and logic, where the output of the RAG-augmented LLM scores approximately twice as high as the off-the-shelf LLM. This demonstrates the strength of GPT4's world model and its ability to go beyond writing tasks and reason on novel information provided via RAG. Regarding transparency, the RAG-augmented LLM (by design) includes references, which we find to be correct and appropriate. This represents a substantial improvement of the writing quality of the LLM, which is likely to make a material difference to the practical useability of LLMs in clinical trial-related writing.

## CONCLUSIONS

Our results suggest that hybrid LLM architectures, such as the RAG methodology we used, offer strong potential for GenAI-powered clinical related writing. From our experience of deploying these models in real-life settings, writing processes can be greatly accelerated which offers substantial benefits. We expect this will lead sponsors for clinical trials to rapidly adopt the LLM technology for trial-related writing work.

#### REFERENCES

[1] Sharma S. How to become a competent medical writer? *Perspect Clin Res.* 2010; 1:33-7

[2] Spence O, Hong K, Onwuchekwa Uba R, Doshi P. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. *Clin Trials*. 2020; 17:99-105

[3] Landray MJ, Haynes R, Reith C. Accelerating clinical trials: time to turn words into action. *Lancet.* 2023; 402:165-168

[4] Biever C. ChatGPT broke the Turing test - the race is on for new ways to assess AI. *Nature.* 2023; 619:686-689

[5] OpenAI. ChatGPT. Software tool based on a large language model. 2023

[6] Huynh LM, Bonebrake BT, Schultis K, Quach A, Deibert CM. New Artificial Intelligence ChatGPT Performs Poorly on the 2022 Self-assessment Study Program for Urology *Urol Pract.* 2023; 10:409-415

[7] OpenAI GPT-4 Technical Report. Arxiv. 2023; abs/2303.08774

[8] Department of Health and Human Services - Food and Drug Administration - Center for Drug Evaluation and Research (CDER). Pulmonary Tuberculosis: Developing Drugs for Treatment; (2022)

[9] Lewis P, Perez E, Piktus A, Petroni F, Karpukhin V, et al. Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks

Proceedings of the 34th International Conference on Neural Information Processing Systems December. 2020; 793:9459– 9474

[10] Gao Y, Xiong Y, Gao X, et al. Retrieval-Augmented Generation for Large Language Models: A Survey rXiv. 2023; 2312.10997

## ACKNOWLEDGEMENTS

The authors would like to thank colleagues Dr Jennifer Griffin and Dr Souparno Bhattacharya for their assistance in conducting this assessment.

# **AUTHOR CONTRIBUTIONS**

N.M.: Methodology, Data processing, LLM and other analysis, Manuscript writing, review, editing

C.v.L.: Methodology, Data processing, LLM and other analysis. Manuscript writing, review, editing

I.E.-M.: Methodology, Data processing, LLM and other analysis

G.R..: Methodology, Data processing, LLM and other analysis

C.M.: Methodology, LLM and other analysis, Manuscript writing, review and editing

All authors contributed to the article and approved the submitted version.

# **COMPETING INTERESTS**

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's Health Care practice and by BCG X, the firm's inhouse data science unit.